8-K: INVO Fertility Reports 2025 Financial Results, Cites Growth

INVO Fertility, Inc. announced its fiscal year 2025 financial results, reporting a 5% increase in revenue to $6.84 million and a narrowed net loss from continuing operations, while also highlighting recent financing and strategic expansions.

Summary

• INVO Fertility reported total revenue of $6,841,250 for fiscal year 2025, a 5% increase from $6,532,000 in fiscal year 2024.
• Consolidated clinic revenue grew 4% to $6,721,057.
• Total revenue from all clinics, including equity method clinics, was $8,021,929, up 4% from the prior year.
• Net loss from continuing operations improved to $(5.3) million from $(7.7) million in the previous year.
• Adjusted EBITDA was $(3.2) million, a decrease from $(2.2) million in FY2024.
• The company completed financing rounds totaling $11.5 million in December 2025 and January 2026.
• Acquired Indiana-based Family Beginnings in February 2026, adding a fourth US clinic.
• Wisconsin Fertility Institute joined the Progyny network, expanding employer-benefit access.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with revenue growth and balance sheet strengthening offset by a decline in Adjusted EBITDA and an increase in net loss attributable to common shareholders.

Positives

• Revenue increased by 5% to $6,841,250 in FY2025.
• Consolidated clinic revenue increased by 4% to $6,721,057.
• Net loss from continuing operations decreased to $(5.3) million from $(7.7) million.
• Secured $11.5 million in aggregate gross proceeds from financing transactions in December 2025 and January 2026.
• Strengthened balance sheet with conversion/retirement of preferred stock and elimination of warrant liabilities.
• Acquired Family Beginnings, adding a fourth US fertility clinic and expanding Midwest presence.
• Wisconsin Fertility Institute joined the Progyny network, broadening access to employer-sponsored patients.
• Issued a new patent for its modified INVOcell device, extending protection through 2040.
• Implemented organic growth initiatives at the Atlanta clinic showing meaningful impact.
• Management believes the balance sheet is the strongest it has been in over three years.

Negatives

• Adjusted EBITDA worsened to $(3.2) million from $(2.2) million in FY2024.
• Total operating expenses increased to $14,078,606 from $13,159,713.
• Loss from operations increased to $(7.2) million from $(6.6) million.
• Significant impairment of intangible assets of $1,397,353 in FY2025.
• Loss from debt extinguishment was $2,135,854 in FY2025, compared to $40,491 in FY2024.
• Net loss attributable to common shareholders was $(25.1) million, a substantial increase from $(9.5) million in FY2024.

Risks

• All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond the Company's control, which may cause actual results to differ materially from anticipated results.
• Factors that may cause actual results to differ materially include those set forth in the Company's filings at www.sec.gov.

Future Outlook

Management believes the fertility care market is supported by favorable long-term demand trends, expanding employer-benefit coverage, increased public awareness, and a supportive environment for IVF. Strategic priorities include driving organic growth, integrating acquisitions, pursuing disciplined acquisitions, and expanding the INVOcell platform's commercial and intellectual property value. The company believes it has moved beyond stabilization into a higher-growth phase.

Management Comments

• "This past year marked an important transition for INVO Fertility marked by meaningful progress across operations, acquisitions, and capital structure, positioning the Company for growth through both organic initiatives and strategic clinic acquisitions moving forward."
• "We believe the business has now moved beyond stabilization and into a higher-growth phase."
• "The financing actions completed around year-end and early 2026 improved our flexibility and clarity of capital structure, while the closing of the Family Beginnings acquisition expanded our clinic network to four operational fertility clinics."
• "As we look to the future, we are optimistic about what lies ahead. With a stronger operational foundation, a growing clinic network, a robust acquisition pipeline, and the improved balance sheet, INVO Fertility is well positioned for the next chapter of its growth."

Industry Context

StockSavvy.ai notes that INVO Fertility's results reflect the ongoing consolidation and expansion within the fertility services sector. The company's focus on both organic growth and strategic acquisitions, coupled with technological innovation like the INVOcell patent, aligns with broader industry trends of increasing demand for ART services driven by expanding employer coverage and public awareness.

Stakeholder Impact

• Shareholders: Potential for increased value through growth initiatives and balance sheet strengthening, but also concerns regarding increased net loss and worsening Adjusted EBITDA.
• Employees: Potential for growth and expansion within the company, with a focus on strengthening the operations team.
• Customers: Continued access to fertility services, with potential for enhanced patient engagement through new technologies.
• Suppliers/Creditors: Improved balance sheet and financing may provide greater confidence in the company's ability to meet obligations.

Next Steps

• Continue driving organic growth across existing clinics.
• Integrate and expand the Family Beginnings acquisition.
• Pursue disciplined acquisitions that can enhance long-term earnings power.
• Continue to expand the commercial and intellectual property value of the INVOcell platform.

Key Dates

Recommendation

The company shows signs of growth with increased revenue and strategic expansion, alongside a strengthened balance sheet. However, the worsening Adjusted EBITDA and significant increase in net loss attributable to common shareholders indicate ongoing financial challenges that warrant a cautious 'hold' approach until profitability improves and the growth strategy demonstrates more consistent financial returns.

Keywords

INVO Fertility, Fertility Clinic, IVF, INVOcell, Financial Results, 8-K, Healthcare, ART